➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Dow
Johnson and Johnson
Medtronic
AstraZeneca

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,452,138

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,452,138
Title:Delivery of biologic therapeutics
Abstract: Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed. In some embodiments, the formulations exhibit a burst release, an initial release, a triphasic release, and release over thirty to ninety days of the biologic therapeutic. In some embodiments, the formulations exhibit reversible precipitation of the biologic therapeutic into precipitates having a diameter of about 50 nm to about 10 .mu.m.
Inventor(s): Trollsas; Mikael (San Jose, CA), Stankus; John (Campbell, CA), Su; James (San Bruno, CA), Hossainy; Syed (hayward, CA), Smith; Joshua Takeshi (Campbell, CA), Askar; Shadid (Round Rock, TX)
Assignee: Abbott Cardiovascular Systems Inc. (Santa Clara, CA)
Application Number:14/142,651
Patent Claims:see list of patent claims

Details for Patent 9,452,138

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial Abbott Cardiovascular Systems Inc. (Santa Clara, CA) 2039-02-26 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Abbott Cardiovascular Systems Inc. (Santa Clara, CA) 2039-02-26 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Abbott Cardiovascular Systems Inc. (Santa Clara, CA) 2039-02-26 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Abbott Cardiovascular Systems Inc. (Santa Clara, CA) 2039-02-26 RX Orphan search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Start Trial Abbott Cardiovascular Systems Inc. (Santa Clara, CA) 2039-02-26 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07   Start Trial Abbott Cardiovascular Systems Inc. (Santa Clara, CA) 2039-02-26 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Abbott Cardiovascular Systems Inc. (Santa Clara, CA) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,452,138

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Merck
AstraZeneca
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.